pacientų akimis LR Seimas 20180 9 19 Akcentai 2 IDEALIAME PASAULYJE 3 NaUJA SENA diskusija apie priemokas 4 NaUJA SENA diskusija apie priemokas 5 Aktualijos Lietuvoje 2018 m ID: 797047
Download The PPT/PDF document "Vaistų reguliavimo tendencijos" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Vaistų
reguliavimo
tendencijos pacientų akimisLR Seimas 2018-09-19
Slide2Akcentai2
Slide3IDEALIAME PASAULYJE3
Slide4NaUJA / SENA diskusija apie priemokas
4
Slide5NaUJA / SENA diskusija apie priemokas
5
Slide6Aktualijos Lietuvoje 2018 m.6
Slide7Rezonansiniai atvejai
7
Slide8PACIENTAMS KYLANTYS klausimai8
Slide9Priemokos nereceptinIAMs vaistams9
Slide10Receptinių VS nERECEPTINIŲ VAISTŲ VARTOJIMAS
10
Slide11Percentage co-payments + limited protectionVHI covering co-paymentsCaps on co-paymentsPoor people exemptFlat co-paymentsSource: WHO Barcelona Office 2018Financial protection is closely linked to co-payment design (medicines)
Improve co-payment design
Stronger financial protection
Slide12Case Example from Blood Cancer Field(TKI generics):Patients welcome that generics may improve patient access to more affordable therapies in many countries. However, we also raise concerns about impact on the treatment outcomes when switched between different products for non-medical reasons, if equivalence of these products’ is still uncertain in terms of quality and efficacySee statement of the CML Advocates Network as of 21 May 2014:http://www.cmladvocates.net/133-generics/35412Patients ask for:reliable proof of quality and equivalence of pharmacokinetics and bioavailabilitycollection of comparative clinical data to ensure comparable efficacyno switching for non-medical reasons in optimal response and toleranceno switching between products of same compound more frequently than once a year to allow consistent follow-up, and in case of loss of response or increased toxicity, switch back or switch treatmentmore frequent monitoring (must: PCR tests, optional: plasma level
testing)
Slide13Recommendations that Do not Cost: by Patients to Patients Record the date when started taking biosimilarTrack and record any changes of quality of life on biosimilarReport any noticeable adverse events to your treating physicianTell your physician that you have been switched to biosimilarBe willing to share your experience with patients communityEvery time you are renewing your prescription ask for the same biosimilar from the same manufacturer. Be ready to show the label / picture of the packaging to the pharmacist13
Slide1414